Helsinn was pleased to be present at the recent European Society for Medical Oncology (ESMO) annual congress, one of most influential (EU) oncology scientific platform […]

Cancer supportive care is a fundamental component of care for patients going through their cancer treatment journey. Research has shown that monitoring symptoms and introducing […]

■ New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and rare disease products■ This new financing agreement replaces prior […]

Lugano, Switzerland, June, 12, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

Solna, Sweden and Lugano, Switzerland, April 13, 2022 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focussed on developing novel contractile agents with a unique mode-of-action […]

Lugano, Switzerland, February 3, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over […]

Lugano, Switzerland, January 10, 2023 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, January 9, 2023 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, January 4, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]